Drugs.com - Clinical Trials

Bracco Imaging Receives FDA Fast Track Designation for BR55

MILAN - February 6, 2025 -- Bracco Imaging, a global leader in diagnostic imaging, announced today that the U.S. FDA has granted Fast Track designation for the development of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection...

Feb 9, 2025 - 21:44
 0
Bracco Imaging Receives FDA Fast Track Designation for BR55
MILAN - February 6, 2025 -- Bracco Imaging, a global leader in diagnostic imaging, announced today that the U.S. FDA has granted Fast Track designation for the development of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection...
Read More

Tags:

Previous Article

Three drug cocktail shows potential to boost CAR-T cancer therapy

Next Article

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgage...

Related Posts

Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity

Spinogenix Completes Phase 2 Study of SPG601 for Treatm...

Feb 13, 2025  0

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Alterity Therapeutics Announces Positive ATH434 Phase 2...

Feb 9, 2025  0

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Granted Fast Track Designation from the U.S. Fo...

Feb 13, 2025  0